These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25931274)

  • 1. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
    Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
    Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
    Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
    Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
    Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
    Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.
    Assal A; Dong B; Khan H; Medavarapu R; Shastri A; Pradhan K; Friedman E; Mantzaris I; Janakiram M; Battini R; Kornblum N; Yu Y; Verma A; Braunschweig I; Derman O
    Leuk Lymphoma; 2016 Oct; 57(10):2452-5. PubMed ID: 26886689
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
    Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
    Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
    Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
    Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
    Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
    [No Abstract]   [Full Text] [Related]  

  • 11. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 14. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
    Takahashi N
    Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
    [No Abstract]   [Full Text] [Related]  

  • 15. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study.
    Jamy O; Godby R; Sarmad R; Costa LJ
    Am J Hematol; 2021 Jul; 96(7):E265-E268. PubMed ID: 33864684
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.
    Hochhaus A
    Ann Oncol; 2006 Sep; 17 Suppl 10():x274-9. PubMed ID: 17018738
    [No Abstract]   [Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.